Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03088020 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Sponsor changed: Debra Weese-Mayer to Ilya Khaytinv13
  2. Notable Primary completion date: Dec 31, 2024 to Dec 31, 2031v12 Show 4 more changesShow less
    • Study completion date: Dec 31, 2025 to Dec 31, 2032
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study description expanded, about 33 words
    • Study title expanded, about 3 words
  3. Minor Re-verified, no change to tracked fieldsv11
  4. Notable Enrollment target: 600 to 1000
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site contact updated
    v10
  5. Notable Primary completion date: Dec 31, 2023 to Dec 31, 2024
    • Study completion date: Dec 31, 2024 to Dec 31, 2025
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Minor Re-verified, no change to tracked fieldsv8
  2. Notable Primary completion date: Dec 31, 2021 to Dec 31, 2023
    • Study completion date: Dec 31, 2022 to Dec 31, 2024
    v7
  3. Minor Site contact updatedv6
  4. Minor Re-verified, no change to tracked fieldsv5
  5. Minor Site contact updatedv4
  6. Notable Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago to Debra Weese-Mayer
    • Enrollment target: 400 to 600
    • Site contact updated
    v3
  7. Minor Re-verified, no change to tracked fieldsv2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Center for Autonomic Medicine in Pediatrics (CAMP), in collaboration with leading CCHS clinicians, scientists, and patient advocacy groups around the world has built the first International CCHS (Congenital Central Hypoventilation Syndrome REDCap (Research Electronic Data Capture) Registry. This registry is an international collaboration to capture CCHS natural history data with CCHS patients and their physicians recruited from around the world. This registry is part of a CCHS natural history study that includes the CCHS Secure Health-hub Advancing Research Efforts (CCHS-SHARE), a natural history data platform shared with the broader CCHS research and patient community to house extensive longitudinal, de-identified data. Inclusion of registry data in CCHS-SHARE is optional. The purpose of this IRB-approved research study is to gain a better understanding of the natural history of CCHS, including the various clinical manifestations of CCHS with advancing age, and as related to each patient's specific PHOX2B mutation. With a better understanding of CCHS natural history, we will be able to better anticipate healthcare needs and to provide more accurate guidelines to healthcare providers world-wide in caring for patients with CCHS. The study aims to obtain detailed phenotypic information (information about health and well-being) on patients with CCHS and their families. Participation would require filling out a confidential survey that asks questions regarding phenotype and past medical history. Involvement in the project is completely voluntary and there is no compensation for taking part. However, this project will help us learn more about this disease, with the goal of advancing treatment.
Trial Details
NCT Number NCT03088020
Lead Sponsor Ilya Khaytin
Collaborators: Northwestern University, The Chicago Community Trust
Conditions
(from sponsor)
Congenital Central Hypoventilation Syndrome
Related terms Congenital central hypoventilation syndrome, Ganglioneuroblastoma, Ganglioneuroma, Hirschsprung Disease, Neuroblastoma
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov